The Food and Drug Administration recently approved gene therapy to treat sickle cell disease among children ages 2 and older, which a Nashville doctor described as a medical milestone.
Learn how gene editing is transforming sickle cell disease treatment and why expanding access to younger children matters.
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug ...
A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered viral vectors throughout the brain.
Stem cell transplantation (also called bone marrow transplantation) and gene therapy are among the most powerful curative ...
HealthDay on MSN
FDA expands use of first sickle cell disease gene therapy for children as young as 2 years
The U.S. Food and Drug Administration has issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent ...
The National Institute on Aging of the National Institutes of Health has awarded a five-year grant initially worth $8.37 ...
The firm announced it has aligned with the US Food and Drug Administration on the design of the Phase III study, which could support a biologics license application.
The 500,000-square-foot facility, designed as a global gene therapy manufacturing complex, spans a full city block along ...
New Vericheck ddPCR™ Kits Combine Highly Specific and Highly Sensitive DNA Detection and Quantification with the QX700™ ...
Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...
Fast, local cryopreservation is a consistent bottleneck for autologous cell therapy developers, even in major cell and gene therapy hubs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results